Every 8-K that Omeros Corporation (OMER) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OMER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMER filings page.
Omeros Corporation expanded its Board of Directors to nine members and appointed Joseph Schocken as a director effective August 12, 2026. His initial term runs until the Company’s 2027 annual meeting of shareholders or earlier resignation or removal.
Schocken, 79, is a private investor and founder and president of Tranceka Capital, LLC, with a long history in investment banking and public-company leadership. He was also a driving participant in national economic policy discussions and the JOBS Act and currently serves as chairman of Taqtile, Inc.
Under Omeros’ non-employee director compensation policy, Schocken received a stock option to purchase 30,000 shares of common stock on his appointment date and will be covered by the Company’s standard director indemnification agreement. He joins the Board’s Audit Committee, and the Company states he has no disclosable material interests in related-party transactions.
Omeros Corporation reported strong second-quarter 2026 results driven by the U.S. launch of YARTEMLEA for TA-TMA. YARTEMLEA generated $32.2 million in gross revenue and $28.5 million in net product sales, a 190% increase in gross revenue from $11.1 million in the first quarter of 2026.
GAAP net income was $13.2 million, or $0.18 per basic share, versus a net loss of $25.4 million a year earlier, aided by an $11.4 million non-cash gain on financial instruments and $6.6 million income from discontinued operations. Non-GAAP adjusted net income was $1.8 million, or $0.02 per share. At June 30, 2026, cash and short-term investments totaled $132.0 million, and operating cash flow was $4.1 million for the quarter. The company repurchased $30.5 million principal of 2029 convertible notes, cutting outstanding principal to $40.3 million, eliminating $8.6 million in future interest and reducing potential dilution from 11.4 million to 6.5 million shares, and also retired 0.8 million common shares for $9.9 million. Omeros disclosed a negative CHMP opinion on its narsoplimab MAA in Europe and has requested re-examination while advancing multiple pipeline programs.
Omeros Corporation reports that on July 20, 2026 it completed the repurchase of approximately $14.5 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 under previously disclosed privately negotiated agreements. The total purchase price, inclusive of accrued and unpaid interest and all other obligations, was approximately $29.0 million. Omeros had previously repurchased $16.0 million principal amount of the same Notes from the same holders. In total, the company has now repurchased and retired $30.5 million aggregate principal amount of these Notes, with approximately $40.3 million principal amount remaining outstanding.
Omeros Corporation is repurchasing a portion of its 9.50% Convertible Senior Notes due 2029 and has agreed to buy more. The company expects to complete the repurchase of $16.0 million aggregate principal amount of Notes on July 6, 2026, for a total purchase price of approximately $31.3 million. After this step, about $54.8 million aggregate principal amount of Notes will remain outstanding.
On July 2, 2026, Omeros also agreed to repurchase additional Notes with an aggregate principal amount of up to approximately $14.5 million for a total purchase price of up to approximately $31.0 million, with pricing tied to an averaging period beginning July 6, 2026. If fully completed, these additional repurchases would leave approximately $40.3 million aggregate principal amount of Notes outstanding, and the company may seek unsecured or limited-collateral debt financing to replace some or all of the cash used.
Omeros Corporation reported the results of its 2026 Annual Meeting of Shareholders held on June 18, 2026. Shareholders of record were entitled to vote 72,168,330 common shares, and 58,010,900 shares were represented in person or by proxy, an 80.04% turnout. The filing lists detailed vote totals for the election of directors, including 20,787,774 shares voted for Thomas J. Cable and 10,531,585 against, and 25,314,641 for Peter A. Demopulos, M.D. and 6,063,216 against. It also provides final for/against/abstain and broker non-vote counts for additional shareholder proposals.
Omeros Corporation entered into privately negotiated agreements to repurchase up to approximately $16.0 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029. The total purchase price, including accrued and unpaid interest and all other obligations, will be up to approximately $34.0 million, subject to adjustment based on the trading price of its common stock during an averaging period beginning on June 18, 2026.
The company expects these repurchases to close between July 6, 2026 and July 16, 2026, following completion of the averaging period. If the full $16.0 million principal amount is repurchased, approximately $54.8 million aggregate principal amount of these Notes will remain outstanding.
Omeros Corporation reported a strong turnaround in first-quarter 2026 results, driven by the U.S. launch of YARTEMLEA. Net income was $56.1 million, or $0.78 per basic share, compared with a net loss of $33.5 million, or $0.58 per share, a year earlier.
Results include a non-cash gain of $73.1 million from marking to market embedded derivatives on 2029 convertible notes; excluding this, non-GAAP adjusted net loss was $17.1 million, or $0.24 per share. YARTEMLEA, launched in January 2026, generated gross product sales of $11.1 million and net sales of $9.9 million in the quarter.
At March 31, 2026, cash and short-term investments totaled $135.3 million. Omeros repaid the remaining $17.1 million principal on its 2026 notes and now has $70.8 million of 2029 notes outstanding. Total operating expenses declined to $27.3 million from $35.0 million a year earlier as R&D spending fell after the Novo Nordisk zaltenibart transaction.
Omeros Corporation reported a sharp turnaround in late 2025, driven by a major asset sale and its first U.S. drug approval. Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, a year earlier. For full-year 2025, net loss narrowed to $3.4 million, or $0.05 per share, from a $156.8 million loss in 2024.
Results reflected a $237.6 million net gain from the zaltenibart transaction with Novo Nordisk and a $136.0 million non-cash loss from marking embedded derivatives on the company’s 2029 Notes and Term Loan. Excluding this non-cash item, non-GAAP adjusted net income was $222.5 million, or $3.14 per share, for the quarter and $133.4 million, or $2.10 per share, for the year.
At December 31, 2025, Omeros held $171.8 million in cash and short-term investments and had $87.9 million in aggregate principal debt, down from $164.9 million a year earlier after using Novo Nordisk proceeds to repay its senior secured term loan and 2026 convertible notes. The company also achieved FDA approval and U.S. launch of YARTEMLEA for TA-TMA, began commercial sales in January 2026, and highlighted progress across its oncology, PDE7, and T-CAT infectious disease programs.
Omeros Corporation disclosed preliminary year-end liquidity figures following an investor call. The company reported that at December 31, 2025, it had approximately $171.5 million in cash and short-term investments available for operations. This amount is described as preliminary and unaudited and may change after the company completes its customary financial closing procedures and adjustments.
The disclosure is provided under a current report and is specifically designated as “furnished” rather than “filed,” meaning it is not subject to certain liability provisions and will not automatically be incorporated into other securities filings.
Omeros Corporation reported that the U.S. Food and Drug Administration has approved YARTEMLEA® (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a serious and often fatal complication of stem-cell transplantation linked to activation of the lectin pathway of complement. The company issued a revised press release on December 24, 2025 to update the date of its YARTEMLEA approval-related conference call and to add supplemental information about the experts quoted, with no other changes to the release.
Omeros Corporation filed a current report to furnish its latest quarterly results. The company issued a press release on November 13, 2025, covering financial results for the three and nine months ended September 30, 2025, and attached this release as Exhibit 99.1.
The report clarifies that the press release and related information are being furnished, not filed, under securities laws, limiting associated liability and preventing automatic incorporation into other regulatory filings unless specifically included.
Omeros entered an Asset Purchase and License Agreement with Novo Nordisk granting exclusive global rights to develop and commercialize zaltenibart (OMS906) and related compounds. Omeros is eligible for up to $2.1 billion, including an upfront cash payment of $240.0 million at closing, up to $510 million in development and approval milestones, and up to $1.3 billion in sales-based milestones. The agreement also provides for tiered royalties on annual net sales at percentage rates ranging from high single digit to high teens.
The transaction is subject to customary conditions, including HSR waiting period expiration or termination, accuracy of representations, covenant compliance, and the absence of a material adverse effect, and is expected to close in the fourth quarter of 2025. At closing, a portion of the $240.0 million will repay the $67.1 million outstanding term loan under the 2024 Credit Agreement, along with related prepayment premiums and accrued interest, releasing all liens and covenants. Omeros retains certain MASP‑3 program rights, including small‑molecule development, and will provide transition services reimbursed by Novo Nordisk.